Giovanni Cossu1, Roberto Ceravolo2, Maurizio Zibetti3, Roberta Arca4, Valeria Ricchi4, Alessandra Paribello4, Daniela Murgia4, Aristide Merola3, Alberto Romagnolo3, Valentina Nicoletti2, Giovanni Palermo2, Alessandra Mereu5, Leonardo Lopiano3, Maurizio Melis4, Giovanni Abbruzzese6, Ubaldo Bonuccelli2. 1. Neurology Unit, Azienda Ospedaliera Brotzu Cagliari, P.le Ricchi 1, 009134, Cagliari Italy. Electronic address: giovannicossu1@gmail.com. 2. Neurology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, Ospedale S. Chiara Via Roma 67, 56126, Pisa, Italy. 3. Neurology Unit, University of Torino, Ospedale Molinette, C.so Bramante, 88, 10126, Torino, Italy. 4. Neurology Unit, Azienda Ospedaliera Brotzu Cagliari, P.le Ricchi 1, 009134, Cagliari Italy. 5. Department of Public Health University, Clinical and Molecular Medicine, University of Cagliari, 09042, Monserrato, Cagliari, Italy. 6. Department of Neurosciences, Ophthalmology & Genetics University of Genova, Via De Toni, 5, 16132, Genova, Italy.
Abstract
OBJECTIVE: Our purpose was to determine whether the use of catechol-O-methyltransferase-inhibitors (ICOMT) can reduce the risk of developing levodopa (LD)-induced neuropathy in Parkinson's disease (PD) patients. METHODS: A multicentre study of 197 PD patients was performed. 144 were exposed to LD for more than three years (LELD group); 53 simultaneously assumed Entacapone for at least eighteen months (LELD_ICOMT group). RESULTS: The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p < 0.0001), the serum Hcy levels were significantly lower (p = 0.001) compared to LELD group. CONCLUSION: Our results suggest that ICOMT could have a protective effect on the development of LD-induced neuropathy. Their action probably occurs through the metabolic rebalancing of the one-carbon-pathway cycle and is independent of the PD duration and severity and the duration of LD intake.
OBJECTIVE: Our purpose was to determine whether the use of catechol-O-methyltransferase-inhibitors (ICOMT) can reduce the risk of developing levodopa (LD)-induced neuropathy in Parkinson's disease (PD) patients. METHODS: A multicentre study of 197 PDpatients was performed. 144 were exposed to LD for more than three years (LELD group); 53 simultaneously assumed Entacapone for at least eighteen months (LELD_ICOMT group). RESULTS: The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p < 0.0001), the serum Hcy levels were significantly lower (p = 0.001) compared to LELD group. CONCLUSION: Our results suggest that ICOMT could have a protective effect on the development of LD-induced neuropathy. Their action probably occurs through the metabolic rebalancing of the one-carbon-pathway cycle and is independent of the PD duration and severity and the duration of LD intake.
Authors: Alberto Romagnolo; Aristide Merola; Carlo Alberto Artusi; Mario Giorgio Rizzone; Maurizio Zibetti; Leonardo Lopiano Journal: Mov Disord Clin Pract Date: 2018-11-08
Authors: Maria Jeziorska; Andrew Atkinson; Lewis Kass-Iliyya; Christopher Kobylecki; David Gosal; Andrew Marshall; Rayaz A Malik; Monty Silverdale Journal: J Parkinsons Dis Date: 2019 Impact factor: 5.568